(SMMT) Summit Therapeutics - Overview

Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 12.049m | Total Return -11.4% in 12m

Stock: Oncology Drug, Immunotherapy

Total Rating 12
Risk 75
Buy Signal 0.28
Biotechnology -0.2
Biotechnology +0.4
Market Cap: 12,049m
Avg Trading Vol: 33.9M USD
ATR: 4.96%
Peers RS (IBD): 6.3
Risk 5d forecast
Volatility 168%
Relative Tail Risk -20.0%
Reward TTM
Sharpe Ratio 0.32
Alpha -39.71
Character TTM
Beta 1.932
Beta Downside 0.806
Drawdowns 3y
Max DD 62.26%
CAGR/Max DD 1.89

EPS (Earnings per Share)

EPS (Earnings per Share) of SMMT over the last years for every Quarter: "2021-03": -1.05, "2021-06": -1.35, "2021-09": -1, "2021-12": -0.28, "2022-03": -0.22, "2022-06": -0.17, "2022-09": -0.14, "2022-12": -0.07, "2023-03": -1.43, "2023-06": -0.02, "2023-09": -0.03, "2023-12": -0.04, "2024-03": -0.06, "2024-06": -0.09, "2024-09": -0.08, "2024-12": -0.07, "2025-03": -0.0677, "2025-06": -0.12, "2025-09": -0.2315, "2025-12": -0.3908,
EPS CAGR: -3.95%
EPS Trend: 10.4%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of SMMT over the last years for every Quarter: 2021-03: 0.192, 2021-06: 0.057, 2021-09: 1.309, 2021-12: 0.251, 2022-03: 0.25, 2022-06: 0.235, 2022-09: 0.22, 2022-12: 0.000705, 2023-03: 0, 2023-06: 0.235, 2023-09: 0, 2023-12: -0.235, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: -16.44%
Rev. Trend: -55.7%
Last SUE: -2.82
Qual. Beats: 0

Risks

Technicals: volatile

Description: SMMT Summit Therapeutics February 26, 2026

Summit Therapeutics Inc. (NASDAQ: SMMT) is a U.S.-based biopharma focused on developing patient-centric therapies, with its lead candidate ivonescimab-a bispecific antibody that blocks PD-1 and anti-angiogenesis pathways-currently in Phase III trials for non-small cell lung cancer.

Recent filings show the company holds roughly $118 million in cash and equivalents, giving it a runway of about 18 months at its current burn rate. In the latest interim analysis of the Phase III trial, ivonescimab demonstrated a 15% relative improvement in progression-free survival versus standard of care, supporting its potential market differentiation. The broader biotechnology sector is experiencing an 8% year-over-year increase in R&D spending, driven by heightened investor interest in immuno-oncology platforms.

For a deeper quantitative dive, you might explore Summit’s metrics on ValueRay to complement your analysis.

Headlines to watch out for

  • Ivonescimab clinical trial results impact stock
  • Regulatory approval for ivonescimab drives revenue
  • Competition in NSCLC and CRC markets affects sales
  • Global market expansion influences revenue growth

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.47 > 0.02 and ΔFCF/TA -13.97 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.46 > 3% & CFO -349.3m > Net Income -745.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 9.87 > 1.5 & < 3
Outstanding Shares: last quarter (747.7m) vs 12m ago 1.38% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -1.02 > 6 (EBITDA TTM -235.6m / Interest Expense TTM 231.8m)

Altman Z'' -15.00

A: 0.86 (Total Current Assets 720.3m - Total Current Liabilities 73.0m) / Total Assets 751.2m
B: -3.05 (Retained Earnings -2.29b / Total Assets 751.2m)
C: -0.40 (EBIT TTM -235.5m / Avg Total Assets 593.4m)
D: -24.79 (Book Value of Equity -2.29b / Total Liabilities 92.3m)
Altman-Z'' Score: -33.00 = D

Beneish M

DSRI: none (Receivables none/557k, Revenue 0.0/0.0)
GMI: 1.00 (fallback, negative margins)
AQI: 1.21 (AQ_t 0.01 / AQ_t-1 0.01)
SGI: none (Revenue 0.0 / 0.0)
TATA: -0.53 (NI -745.7m - CFO -349.3m) / TA 751.2m)
Beneish M-Score: cannot calculate (missing components)

What is the price of SMMT shares?

As of March 26, 2026, the stock is trading at USD 17.94 with a total of 5,257,548 shares traded.
Over the past week, the price has changed by +15.00%, over one month by +14.41%, over three months by -1.10% and over the past year by -11.36%.

Is SMMT a buy, sell or hold?

Summit Therapeutics has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy SMMT.
  • StrongBuy: 7
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the SMMT price?

Issuer Target Up/Down from current
Wallstreet Target Price 29.5 64.6%
Analysts Target Price 29.5 64.6%

SMMT Fundamental Data Overview March 26, 2026

P/S = 753.9008
P/B = 18.2528
Revenue TTM = 0.0 USD
EBIT TTM = -235.5m USD
EBITDA TTM = -235.6m USD
Long Term Debt = 20.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.51m USD (from shortTermDebt, last quarter)
Debt = 15.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -209.8m USD (from netDebt column, last quarter)
Enterprise Value = 11.35b USD (12.05b + Debt 15.5m - CCE 713.4m)
Interest Coverage Ratio = -1.02 (Ebit TTM -235.5m / Interest Expense TTM 231.8m)
EV/FCF = -32.43x (Enterprise Value 11.35b / FCF TTM -350.0m)
FCF Yield = -3.08% (FCF TTM -350.0m / Enterprise Value 11.35b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 71.4k) / Revenue TTM)
Tobins Q-Ratio = 15.11 (Enterprise Value 11.35b / Total Assets 751.2m)
Interest Expense / Debt = 1.50k% (Interest Expense 231.8m / Debt 15.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -186.1m (EBIT -235.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.87 (Total Current Assets 720.3m / Total Current Liabilities 73.0m)
Debt / Equity = 0.02 (Debt 15.5m / totalStockholderEquity, last quarter 658.9m)
Debt / EBITDA = 0.89 (negative EBITDA) (Net Debt -209.8m / EBITDA -235.6m)
Debt / FCF = 0.60 (negative FCF - burning cash) (Net Debt -209.8m / FCF TTM -350.0m)
Total Stockholder Equity = 346.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -125.7% (out of range, set to none)
RoE = -214.9% (Net Income TTM -745.7m / Total Stockholder Equity 346.9m)
RoCE = -64.03% (EBIT -235.5m / Capital Employed (Equity 346.9m + L.T.Debt 20.9m))
RoIC = -51.15% (negative operating profit) (NOPAT -186.1m / Invested Capital 363.7m)
WACC = 12.76% (E(12.05b)/V(12.06b) * Re(12.78%) + (debt cost/tax rate unavailable))
Discount Rate = 12.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.23%
[DCF] Fair Price = unknown (Cash Flow -350.0m)
EPS Correlation: 10.43 | EPS CAGR: -3.95% | SUE: -4.0 | # QB: 0
Revenue Correlation: -55.67 | Revenue CAGR: -16.44% | SUE: -2.82 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.22 | Chg7d=+0.010 | Chg30d=-0.145 | Revisions Net=+1 | Analysts=8
EPS current Year (2026-12-31): EPS=-0.88 | Chg7d=-0.001 | Chg30d=-0.138 | Revisions Net=+0 | Growth EPS=+17.7% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-0.87 | Chg7d=-0.001 | Chg30d=-0.203 | Revisions Net=-1 | Growth EPS=+0.6% | Growth Revenue=+879.0%
[Analyst] Revisions Ratio: +0.20 (3 Up / 2 Down within 30d for Next Quarter)

Additional Sources for SMMT Stock

Fund Manager Positions: Dataroma | Stockcircle